Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 24Kidney Neoplasms 10Neoplasms 9Carcinoma 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasm Metastasis 3Melanoma 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Lung Neoplasms 2Kidney Diseases 2Glioblastoma 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2cT2a N0NxM0 Renal Tumor 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumors 1Solid Tumors 1Solid Malignancies 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Refractory or Recurrent Solid Tumors, Excluding CNS Tumors 1Prostatic Neoplasms 1

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × Axitinib × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡